Goodwill and Other Intangible Assets
The Company's goodwill was $7.0 million as of December 31, 2016 and December 31, 2015, respectively. All goodwill resides in the PCT reporting unit.
The Company's intangible assets and related accumulated amortization, all of which resides in the PCT reporting segment, as of December 31, 2016 and December 31, 2015 consisted of the following (in thousands):
 
 
 
December 31, 2016
 
December 31, 2015
 
Useful Life
 
Gross
 
Accumulated Amortization
 
Net
 
Gross
 
Accumulated Amortization
 
Net
Customer list
10 years
 
$
1,000.0

 
$
(595.1
)
 
$
404.9

 
$
1,000.0

 
$
(495.1
)
 
$
504.9

Manufacturing technology
10 years
 
3,900.0

 
(2,320.9
)
 
1,579.1

 
3,900.0

 
(1,930.9
)
 
1,969.1

Tradename
10 years
 
800.0

 
(476.1
)
 
323.9

 
800.0

 
(396.1
)
 
403.9

Total Intangible Assets
 
 
$
5,700.0

 
$
(3,392.1
)
 
$
2,307.9

 
$
5,700.0

 
$
(2,822.1
)
 
$
2,877.9


 
As of December 31, 2015, the Company determined that IPR&D valued at $34.3 million and goodwill valued at $18.2 million were impaired, as a result of the discontinuation of the Company's CLBS20 Phase 3 clinical study. As of June 30, 2015, the Company determined that IPR&D valued at $9.4 million was impaired as a result of the Company's decision that it would not pursue further development of CLBS10. Total intangible amortization expense was classified in the operating expense categories for the periods included below as follows (in thousands):
 
Year Ended December 31,
 
2016
 
2015
Cost of revenue
$
314.2

 
$
316.8

Research and development
75.8

 
108.4

Selling, general and administrative
180.0

 
180.0

Total
$
570.0

 
$
605.2



Estimated intangible amortization expense on an annual basis for the succeeding five years is as follow (in thousands):

2017
$
570.0

2018
570.0

2019
570.0

2020
570.0

2021
27.9

 
$
2,307.9

Historical Timeline

Fiscal YearFiled
2016Mar 17, 2017Showing above
2015Mar 15, 2016

About Goodwill & Intangibles Disclosures

Goodwill and intangible asset disclosures reveal the premium paid in acquisitions and how management assesses whether that premium retains its value. Since goodwill is no longer amortized under US GAAP, the annual impairment test is the only mechanism that adjusts carrying values downward — making the assumptions behind that test critically important for investors.

Key signals: a history of goodwill impairments suggests management consistently overpays for acquisitions. Watch the gap between reporting unit fair value and carrying amount — when fair value exceeds carrying amount by less than 10-20%, a small decline in business performance could trigger a write-down. For finite-lived intangibles, examine useful life assumptions across customer relationships, technology, and trade names; aggressive estimates inflate near-term earnings. Compare total intangibles-to-total-assets ratios against peers to assess acquisition dependency. Rising goodwill as a percentage of equity can signal balance sheet fragility.